ClinicalTrials.gg
TerminatedNCT06484920Updated Nov 17, 2026Results posted

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

A Phase 2 interventional study of ATRA and Pembrolizumab in Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by Rita Assi. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Rita Assi · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Why this study was terminated
Loss of research support
Updated Nov 17, 2026Now TerminatedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing pembrolizumab in Hodgkin Disease — 12 open to participants now, 20 under way, 2 of them phase 3. pembrolizumab · Hodgkin Disease.

Enrollment
28th of 30
1 · median 34
Started
2024
with 4 others
Phase 2
22 of 30
10 open now
Registered
25th of 30
by date

Among the 30 studies testing pembrolizumab in Hodgkin Disease, this one is the 28th largest by enrollment, is one of 5 that started in 2024, is one of 22 in phase 2, and was the 25th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

12 of the 30 studies testing pembrolizumab in Hodgkin Disease are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pembrolizumab in Hodgkin Disease, or all of them as a file.
02

Study summary

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

03

Conditions studied

  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old at the time of
  2. Ability to provide written informed consent and HIPAA authorization
  3. Willingness to comply with all study procedures and be available for the duration of the trial
  4. Have a performance status of 0 to 2 on the Performance Scale.
  5. ≥12 weeks as per investigator discretion
  6. Patients with proven, HL or B-NHL as follows:

    1. HL after failure of at least 1
    2. Primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line therapy
    3. Other B-cell NHLs after failure of at least 2 prior lines of systemic therapy. The eligible types of B-cell NHLs are:

    i. Diffuse large B cell lymphoma ii. Follicular lymphoma iii. Marginal Zone lymphoma iv. Mantle Cell Lymphoma d. Indolent lymphoma are only eligible if they require systemic treatment e. Lymphocyte predominant HL are eligible Note: Formalin-fixed, paraffin embedded from the primary cancer must be available for testing. If not available or sufficient, patients will be asked to undergo an US or CT guided biopsy prior to study entry to satisfy this eligibility criterion.

  7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 10 days prior to the first study treatment: Hematological (ANC) ≥1,500 /mcL ≥100,000 / mcL ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment) and aPTT ≤1.5 x ; this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. Renal calculated ( can also be used in place of creatinine or CrCl) calculated creatinine clearance ≥ 60 mL/min Hepatic Serum total

    • 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN (patients with known Gilbert disease who have bilirubin levels ≤ 3 x ULN may be enrolled). Patients must be able to undergo biliary stenting if required before or, if required, during the trial (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR
    • 5 X ULN for subjects with liver Albumin >2.5 mg/dL
  8. Female subject of should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: Female of childbearing potential definition: (ECOG definition) Any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    1. Has not undergone a hysterectomy or bilateral oophorectomy; or
    2. Has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  9. Female subjects of childbearing potential must be willing to use an adequate method of for the course of the study through 120 days after the last dose of study medication.

    Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

    Refer to section 8.4.1 for more information.

  10. Male subjects of childbearing potential must agree to use an adequate method of contraception of the protocol, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Refer to section 8.4.1 for more information.
  11. Acceptable methods of contraception include IUD, oral contraceptive, subdermal implant, and double barrier (condom with a contraceptive sponge or contraceptive pessary). Micro-dosed progesterone preparations ("mini-pill") are an inadequate method of contraception during treatment with ATRA. If patients are taking this pill they should be instructed to stop, and another form of contraceptive should be prescribed instead.
  12. Patients with a history of CAR-T cell therapy are eligible if ≥ 3 months post treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  2. Known and/or . Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to first dose of study treatment.
  3. Significant reduction in performance status between the screening/ baseline visit and within 72 hours prior to commencement of treatment as per trial protocol, as per the Investigator's assessment, defined as a reduction in ECOG score to 3 or 4.
  4. Patients with a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of therapy (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) within 7 days prior to the first dose of trial treatment.

    Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

  5. to pembrolizumab or any of its .
  6. to the use of ATRA including but not limited to: patients with a history of hypersensitivity reaction to tretinoin, vesanoid or related compounds ( i.e. acitretin, isotretinoin, vitamin A); , Tetracyclines, Progesterone (low dose), drugs inducing P450 (rifampicin, glucocorticoids, phenobarbital, etc), ketoconazole and drugs inhibiting p450 (cimetidine, erythromycin, cyclosporine, etc); antifibrinolytic agents (e.g. tranexamic acid, aminocaproic acid, aprotinin) and hydroxyurea)
  7. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  8. Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Subjects with chronic conditions such as vision changes or prior hearing loss that is not reasonably expected to be exacerbated by the investigational product may be included. Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: Subjects with Grade 2 adrenal insufficiency or thyroid conditions who are not expected to resolve to baseline, are on a stable dose of medication may be included if it is not reasonably expected to be exacerbated by the investigational product, and asymptomatic whilst on treatment.
  9. History of in the last 5 years with the exception of prior history of in situ cancer or basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
  10. Patient has undergone major surgery, other than diagnostic surgery (i.e., surgery done to obtain a for diagnosis without removal of an organ), within 4 weeks prior to Day -1 of treatment in this study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  11. Known history of, or any evidence of active, non-infectious pneumonitis.
  12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  13. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  14. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  15. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
  16. Patients on micro-dosed progesterone preparations ("mini-pill") who are unwilling to receive an alternative form of .
  17. Prior therapy with an , anti-PD-L1, or anti-PD-L2 agent.
  18. Known history of (HIV) (HIV 1/2 antibodies)
  19. Known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected).
  20. known history of active TB (Bacillus Tuberculosis).
  21. Receipt of within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  22. Patients who receive a COVID shot and/or booster within 4 weeks of Cycle 1 Day -1.
  23. Known sensitivity to retinoic acid derivatives.
  24. Patient is taking any prohibited concurrent medication, including Vitamin A supplements, and modulators (inducers and inhibitors) and is unwilling to stop use ( of 3 days for this protocol) prior to treatment start and during the trial.
  25. History of allogenic stem cell transplant or received a solid organ transplant. Note: If history of transplant is ≥ 5 years, subjects may be deemed eligible at the discretion of the treating physician. Note: Patients with a history of stem cell transplant performed for lymphoma are eligible.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    ATRA and Pembrolizumab

    Patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 ATRA orally for 3 days surrounding each of the first four infusions of pembrolizumab (day -1, day 0, day +1).

    Drug: ATRA · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: Percentage of Patients With Treatment-Related Adverse Events

    Percentage of patients who had a treatment-related (possible, probable, or definite) adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: On treatment date to end of study (up to 1 month)

Secondary outcomes

  1. Overall Response Rate (Percentage of Patients With Complete Response or Partial Response)

    Overall response rate (ORR) was defined as the percentage of the participants who had complete response (CR) or partial response (PR) per Lugano Classification. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product of perpendicular diameters for up to 6 target measurable nodes and extranodal lesions).

    Time frame: On treatment date to end of study

  2. Complete Remission Rate

    Complete remission rate (ORR) was defined as the percentage of the participants who had complete response (CR) per Lugano Classification. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions.

    Time frame: On treatment date to end of study

  3. Change in Patient Derived Myeloid-derived Suppressor Cells (MDSC)

    Assessing the anti-tumor effect of the combination of pembrolizumab and ATRA on the reduction in myeloid-derived suppressor cells (MDSC) frequency through in vitro experiments using patient-derived MDSCs.

    Time frame: Screening, before cycle 2, before cycle 4, and within 60 days after cycle 4 day 1

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneATRA and Pembrolizumab
Started1
Completed0
Not completed1
Withdrew: Death1

Outcome measures

PrimarySafety: Percentage of Patients With Treatment-Related Adverse Events

Percentage of patients who had a treatment-related (possible, probable, or definite) adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Time frame:
On treatment date to end of study (up to 1 month)
Reported as:
Count of participants · Participants
Safety: Percentage of Patients With Treatment-Related Adverse Events
ParticipantsATRA and Pembrolizumab
Safety: Percentage of Patients With Treatment-Related Adverse Events1
SecondaryOverall Response Rate (Percentage of Patients With Complete Response or Partial Response)

Overall response rate (ORR) was defined as the percentage of the participants who had complete response (CR) or partial response (PR) per Lugano Classification. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product of perpendicular diameters for up to 6 target measurable nodes and extranodal lesions).

Time frame:
On treatment date to end of study
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryComplete Remission Rate

Complete remission rate (ORR) was defined as the percentage of the participants who had complete response (CR) per Lugano Classification. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions.

Time frame:
On treatment date to end of study

No measurements were reported for this outcome.

SecondaryChange in Patient Derived Myeloid-derived Suppressor Cells (MDSC)

Assessing the anti-tumor effect of the combination of pembrolizumab and ATRA on the reduction in myeloid-derived suppressor cells (MDSC) frequency through in vitro experiments using patient-derived MDSCs.

Time frame:
Screening, before cycle 2, before cycle 4, and within 60 days after cycle 4 day 1

No measurements were reported for this outcome.

Adverse events

Collected over From on treatment date to end of study (1 month). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATRA and Pembrolizumab1/1 (100%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventATRA and Pembrolizumab
Multi-organ failureGeneral disorders1/1
Acute kidney injuryRenal and urinary disorders1/1
Most frequent other events
Showing 10 of 13
Most frequent other events
EventATRA and Pembrolizumab
AnorexiaMetabolism and nutrition disorders1/1
Blurred visionEye disorders1/1
ConfusionPsychiatric disorders1/1
DizzinessNervous system disorders1/1
EncephalopathyNervous system disorders1/1
FungemiaInfections and infestations1/1
HypotensionVascular disorders1/1
NauseaGastrointestinal disorders1/1
Pulmonary edemaRespiratory, thoracic and mediastinal disorders1/1
SepsisInfections and infestations1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ATRA and Pembrolizumab
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)ATRA and Pembrolizumab
Female0
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ATRA and Pembrolizumab
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATRA and Pembrolizumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ATRA and Pembrolizumab
United States1
ECOG Performance Status
ECOG Performance Status(participants)ATRA and Pembrolizumab
00
11
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Jun 2025, 6 months.

Results were first posted in Nov 2026, 1 year 5 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2027 → Jun 2025 and completion Sep 2029 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jul 3, 2024
StartActual
Nov 18, 2024
Primary completionActual
Jun 3, 2025was Dec 2027
CompletionActual
Jun 3, 2025was Sep 2029
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Loss of research support
changed Nov 17, 2026
Results
Results posted
posted Nov 17, 2026
Primary completion
Dec 2027→Jun 3, 2025 (actual)
Nov 17, 2026
Study completion
Sep 2029→Jun 3, 2025 (actual)
Nov 17, 2026
Enrollment
24 (estimated)→1 (actual)
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of Adverse EventsNow Safety: Percentage of Patients With Treatment-Related Adverse EventsTime frame: from start of treatment through 90 days safety follow-up visit → On treatment date to end of study (up to 1 month)
Nov 17, 2026
Documents
Secondary outcomes
2 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedChange in Patient derived myeloidDerived Myeloid-derived suppressor cellsSuppressor Cells (MDSC)Time frame: Screening, before cycle 2, before cycle 4, and within 60 days after cycle 4 day 1
  • ChangedBefore Overall Response RateNow Overall Response Rate (Percentage of Patients With Complete Response or Partial Response)Time frame: Screening to up to 2 years post last therapy → On treatment date to end of study
  • Time frameComplete Remission RateScreening to up to 2 years post last therapy → On treatment date to end of study
  • DescriptionComplete Remission Rate: how it is measured was reworded
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Terminated
    Why stopped Loss of research support
    Results posted
    Primary completion Dec 2027→Jun 3, 2025 (now actual)
    Study completion Sep 2029→Jun 3, 2025 (now actual)
    Enrollment 24 (estimated)→1 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of Adverse EventsNow Safety: Percentage of Patients With Treatment-Related Adverse EventsTime frame: from start of treatment through 90 days safety follow-up visit → On treatment date to end of study (up to 1 month)
    Secondary outcomes 2 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedChange in Patient derived myeloidDerived Myeloid-derived suppressor cellsSuppressor Cells (MDSC)Time frame: Screening, before cycle 2, before cycle 4, and within 60 days after cycle 4 day 1
    • ChangedBefore Overall Response RateNow Overall Response Rate (Percentage of Patients With Complete Response or Partial Response)Time frame: Screening to up to 2 years post last therapy → On treatment date to end of study
    • Time frameComplete Remission RateScreening to up to 2 years post last therapy → On treatment date to end of study
    • DescriptionComplete Remission Rate: how it is measured was reworded
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06484920
Lead sponsor
Rita Assi
Responsible party
Rita Assi (Assistant Professor of Medicine, Indiana University) — Sponsor-investigator
First posted
Jul 3, 2024
Start date
Nov 18, 2024
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Rita Assi, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tretinoin · Pembrolizumab

Start the discussion